A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
Dominik Bettenworth(University Hospital Münster), Florian Rieder(Cleveland Clinic), Stuart A. Taylor(Brighton and Sussex Medical School), Ilyssa O. Gordon(Cleveland Clinic), David H. Bruining(Mayo Clinic), Iris Dotan(Tel Aviv University), Britta Siegmund(Humboldt-Universität zu Berlin), William J. Sandborn(University of San Diego), Joel G. Fletcher(Mayo Clinic), Bram Verstockt(Universitair Ziekenhuis Leuven), Cathy Lu(University of Calgary), Julián Panés(Hospital Clínic de Barcelona), Axel Dignaß(Goethe University Frankfurt), Siew C. Ng(Chinese University of Hong Kong), Jordi Rimola(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Brian G. Feagan(Western University), Christina Ha(Cedars-Sinai Medical Center), Willem A. Bemelman(Vrije Universiteit Amsterdam), Gerhard Rogler(University Hospital of Zurich), Roger Feakins(Royal Free London NHS Foundation Trust), Phillip Fleshner(Cedars-Sinai Medical Center), Geert d’Haens(Amsterdam University Medical Centers), Mark E. Baker(Cleveland Clinic), Vipul Jairath(Western University), Ren Mao(Sun Yat-sen University), G.T. Henderson, Mark S. Silverberg(Sinai Health System), Ruishen Lyu(Cleveland Clinic Lerner College of Medicine), André D’Hoore
Cited by 79
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k